$218.45 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This Quarter

Equities analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to announce $218.45 million in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Myriad Genetics’ earnings, with the highest sales estimate coming in at $226.28 million and the lowest estimate coming in at $215.75 million. Myriad Genetics posted sales of $194.00 million during the same quarter last year, which suggests a positive year over year growth rate of 12.6%. The business is expected to announce its next quarterly earnings report on Tuesday, February 5th.

On average, analysts expect that Myriad Genetics will report full year sales of $872.12 million for the current financial year, with estimates ranging from $859.02 million to $891.40 million. For the next fiscal year, analysts expect that the business will post sales of $939.49 million, with estimates ranging from $895.80 million to $1.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.13. The company had revenue of $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. Myriad Genetics’s revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 earnings per share.

MYGN has been the subject of several recent research reports. BidaskClub downgraded Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. ValuEngine downgraded Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 12th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research report on Friday, August 24th. TheStreet downgraded Myriad Genetics from a “b” rating to a “c” rating in a research report on Thursday, November 8th. Finally, Barclays raised their price target on Myriad Genetics from $35.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 22nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $41.90.

Myriad Genetics stock traded up $0.19 during mid-day trading on Monday, hitting $32.24. 1,056,150 shares of the company were exchanged, compared to its average volume of 1,100,902. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.83 and a current ratio of 3.17. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 26.87, a PEG ratio of 1.86 and a beta of 0.51. Myriad Genetics has a 12-month low of $27.27 and a 12-month high of $50.44.

Several large investors have recently made changes to their positions in MYGN. Quantbot Technologies LP purchased a new stake in shares of Myriad Genetics during the third quarter worth about $130,000. Robecosam AG boosted its position in shares of Myriad Genetics by 39.8% during the second quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after buying an additional 1,193 shares during the period. First Quadrant L P CA acquired a new position in shares of Myriad Genetics during the third quarter worth approximately $201,000. Ibex Investors LLC acquired a new position in shares of Myriad Genetics during the third quarter worth approximately $202,000. Finally, Parametrica Management Ltd acquired a new position in shares of Myriad Genetics during the third quarter worth approximately $204,000. 98.21% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Further Reading: Bond

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit